MedTrace Logo

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2025-11-12

Study results available
· View outcomes & findings →

Summary

Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia

Conditions

  • Alopecia, Androgenetic

Interventions

DRUG

TDM-105795, 0.0025%

The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

DRUG

TDM-105795, 0.02%

The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

DRUG

TDM-105795 topical vehicle solution

The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

Sponsors & Collaborators

  • Therapeutics, Inc.

    collaborator INDUSTRY

  • Technoderma Medicines Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel J. Piacquadio, M.D. · Therapeutics Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2023-11-08
Completion
2024-01-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05802173 on ClinicalTrials.gov